Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Public ClinicalTrials.gov record NCT01789281. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multi-center Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study and Are Judged by the Investigator to Benefit From Continued Everolimus Treatment
Study identification
- NCT ID
- NCT01789281
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 34 participants
Conditions and interventions
Conditions
Interventions
- Everolimus Drug
- Sandostatin LAR Depot Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 13, 2013
- Primary completion
- Aug 27, 2020
- Completion
- Aug 27, 2020
- Last update posted
- Jun 10, 2021
2013 – 2020
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Hematology Oncology Services of Arkansas SC | Little Rock | Arkansas | 72205 | — |
| Rocky Mountain Cancer Centers SC | Greenwood Village | Colorado | — | — |
| Stamford Hospital | Stamford | Connecticut | 06902 | — |
| H Lee Moffitt Cancer Center and Research Institute SC-2 | Tampa | Florida | 33612 | — |
| Central Indiana Cancer Centers SC | Indianapolis | Indiana | 46227 | — |
| Crescent City Research Consortium, LLC SC-3 | Metairie | Louisiana | 70006 | — |
| Mayo Clinic SC-2 | Rochester | Minnesota | 55905 | — |
| Washington University School of Medicine Dept of Oncology | St Louis | Missouri | 63110 | — |
| Nebraska Cancer Specialists Onc Dept | Omaha | Nebraska | 68154 | — |
| Clinical Research Alliance | Lake Success | New York | 11042 | — |
| New York University Medical Center SC-4 | New York | New York | 10016 | — |
| Oregon Health and Science University SC-8 | Portland | Oregon | 97239 | — |
| Utah Cancer Specialists Utah Cancer (2) | Salt Lake City | Utah | 84106 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01789281, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 10, 2021 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01789281 live on ClinicalTrials.gov.